A
2.49
-0.10 (-3.68%)
| Previous Close | 2.58 |
| Open | 2.50 |
| Volume | 884,535 |
| Avg. Volume (3M) | 2,221,416 |
| Market Cap | 250,264,336 |
| Price / Book | 0.570 |
| 52 Weeks Range | |
| Earnings Date | 12 May 2025 - 20 May 2025 |
| Diluted EPS (TTM) | -2.50 |
| Total Debt/Equity (MRQ) | 1.59% |
| Current Ratio (MRQ) | 18.10 |
| Operating Cash Flow (TTM) | -303.92 M |
| Levered Free Cash Flow (TTM) | -216.69 M |
| Return on Assets (TTM) | -29.73% |
| Return on Equity (TTM) | -44.54% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | ACELYRIN, INC. | Bearish | Bearish |
AIStockmoo Score
1.5
| Analyst Consensus | 1.0 |
| Insider Activity | NA |
| Price Volatility | 0.5 |
| Technical Moving Averages | 5.0 |
| Technical Oscillators | -0.5 |
| Average | 1.50 |
|
Acelyrin Inc is a late-stage clinical biopharmaceutical company. The clinical biopharma segment researches and develops treatments for diseases with pathology related to excess activation of the immune system. It is focused on providing patients with life-changing new treatment options by identifying, acquiring, and accelerating the development and commercialization of transformative medicines. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| % Held by Insiders | 8.08% |
| % Held by Institutions | 105.69% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Tybourne Capital Management (Hk) Ltd | 31 Dec 2024 | 2,906,629 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 6.00 (HC Wainwright & Co., 141.45%) | Hold |
| Median | 4.50 (81.09%) | |
| Low | 3.00 (Citigroup, 20.72%) | Hold |
| Average | 4.50 (81.09%) | |
| Total | 2 Hold | |
| Avg. Price @ Call | 2.20 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Citigroup | 07 Jan 2025 | 3.00 (20.72%) | Hold | 2.20 |
| HC Wainwright & Co. | 07 Jan 2025 | 6.00 (141.45%) | Hold | 2.20 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |